Sarepta's Gene Therapy Dream Is Turning Into a Nightmare

Sarepta pulled in $898.7 million in Elevidys revenue during 2025. That sounds impressive until you look at the trajectory. In Q1 2025, the therapy generated $375 million. By Q4, that had cratered to $110.4 million after the safety events spooked doctors and patients alike.

The first half of 2026 hasn't been much better: just $200.1 million in Elevidys sales across six months. Analysts say the drug is "stabilizing rather than reaccelerating," which is Wall Street code for "this franchise is in trouble."

So Sarepta is cutting deep. The company said its restructuring should save about $400 million annually, with the 500-person layoff alone generating roughly $120 million in yearly cash savings. That's not trimming fat; that's survival mode. Sarepta originally issued $980 million in aggregate principal of senior notes due in 2027, though extensive refinancing has since reduced the outstanding balance to approximately $158.6 million.

The company is also pausing most of its limb-girdle muscular dystrophy gene therapy programs and pivoting toward its siRNA (a different type of genetic medicine) platform instead. Translation: Sarepta is quietly backing away from the very technology that made it famous.

The Bigger Problem for Gene Therapy

Sarepta's crisis isn't happening in a vacuum. It's the loudest alarm bell in a chorus of warnings about AAV gene therapy safety across the entire industry.

AAV (adeno-associated virus) is the most popular delivery vehicle for gene therapies. Scientists load a working copy of a gene into this tiny virus, inject it into a patient, and let the virus deliver the genetic payload to cells. It's an elegant idea, like using a drone to deliver a package directly to someone's front door. The problem? At high doses, the body's immune system can treat that drone like an invader, triggering dangerous inflammation in the liver, heart, or kidneys.

The pattern keeps repeating. Reviews of clinical data have flagged myocarditis (heart inflammation), thrombotic microangiopathy (a blood clotting disorder that can damage kidneys), and liver toxicity as recurring problems, especially at the high doses needed for diseases like muscular dystrophy.

And companies are voting with their feet. Biogen shut down all its AAV gene therapy programs in September 2025. Pfizer, Vertex, and Takeda have similarly pulled back from the space. The industry's enthusiasm for AAV gene therapy, once white-hot, is cooling fast.

What This Means for DMD Patients

For families dealing with Duchenne muscular dystrophy, this is especially painful. DMD is relentless; it typically appears in early childhood and progressively robs boys of their ability to walk, then breathe, then survive. Every year matters.

Elevidys remains the only FDA-approved gene therapy for DMD, and it still has its approval for ambulatory patients. But the black box warning creates a chilling effect. Doctors and parents who were already agonizing over a one-time, irreversible gene therapy now have even more reason to hesitate.

The alternatives are limited. Exon-skipping drugs (like Exondys 51 and Vyondys 53) work only for specific genetic mutations and don't cure the disease. Corticosteroids slow progression but come with brutal side effects. Duvyzat, a newer oral medication that works across all DMD genetic variants, offers some hope, but it's not a gene therapy and doesn't replace the missing dystrophin protein the way Elevidys was designed to.

No other gene therapy competitor is close to market. The pipeline programs that might have offered alternatives are mostly in early-stage trials, and the AAV safety concerns are making investors and companies think twice about pushing them forward.

The Road Ahead

Sarepta is guiding to $1.2 billion to $1.4 billion in total revenue for 2026, leaning on its older RNA-based therapies and whatever Elevidys demand holds up. But the company's stock has been hammered, its workforce is shrinking, and its flagship product now carries the scarlet letter of pharmaceutical safety warnings.

The FDA has also required a postmarketing observational study to further assess the liver injury risk, which means this story isn't over. More data will come in. More scrutiny will follow.

For the gene therapy field broadly, Sarepta's fall from grace is a sobering reminder: delivering genes into the human body is still incredibly hard, and the gap between scientific ambition and clinical reality remains wide. The dream of one-shot genetic cures hasn't died, but it just got a lot more complicated.